European shares slip as oil rises; Novartis plunges 8.8%

  • European shares declined as oil prices increased and Novartis reported another drug-development setback.
  • Novartis shares tumbled 8.8% after del-desiran failed its primary endpoint in late-stage testing.
  • Brent crude futures traded at $98.5 per barrel after Iran threatened Gulf energy infrastructure.

European stocks edged lower on Tuesday as higher oil prices intensified inflation and supply concerns linked to a prolonged Middle East conflict. The pan-European STOXX 600 was down 0.2% at 648.41 points by 0705 GMT, while Germany's DAX fell 0.3%, London's FTSE was flat and France's CAC 40 declined 0.4% after a subdued Monday session during a U.S. public holiday. Novartis dropped 8.8% after its del-desiran treatment for myotonic dystrophy failed to meet its primary endpoint in late-stage testing, following a separate pelacarsen setback announced Monday. Brent crude futures traded at $98.5 per barrel after Iran threatened retaliation against further attacks by targeting Gulf energy infrastructure, including U.S. oil and gas interests. Sandoz rose 2.9% after setting an objective to more than double net sales between 2025 and 2035, while Poste Italiane fell 0.2% after sweetening its offer for Telecom Italia in a bid to gain control of Italy's former phone monopoly.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.